Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06389487
Other study ID # 222253
Secondary ID 2023-510190-34-0
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 29, 2024
Est. completion date April 25, 2025

Study information

Verified date May 2024
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to demonstrate the immune response and to evaluate safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for respiratory syncytial virus (RSV) disease, compared to older adults (OA) (>=) 60 YOA and above


Recruitment information / eligibility

Status Recruiting
Enrollment 850
Est. completion date April 25, 2025
Est. primary completion date August 12, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants and/or participant's parent(s)/ Legally acceptable representative (LAR) who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiary, attend study site visits, ability to access and utilize a phone or other electronic communications). - Written or witnessed informed consent obtained from the participant/participant's parent(s)/LAR(s) (participant must be able to understand the informed consent) prior to performance of any study-specific procedure. Written informed assent obtained from the participant (participant must be able to understand the informed assent) if he/she is less than the legal age prior to performance of any study-specific procedure. Specific inclusion criteria for all participants in Cohort 1 • A male or female participant 18-49 YOA at the time of the study intervention administration. - Participants should be diagnosed with at least 1 of the following medical conditions if considered medically stable by the investigator: - Chronic cardiopulmonary disease resulting in activity restricting symptoms or use of long term medication: o Chronic obstructive pulmonary disease (COPD) o Asthma o Cystic fibrosis o Other chronic respiratory diseases: lung fibrosis, restrictive lung disease, interstitial lung disease, emphysema or bronchiectasis o Chronic heart failure: o Pre-existing Coronary Artery Disease (CAD) (CAD not otherwise specified) - Cardiac arrhythmia - Diabetes mellitus: types 1 or 2 with active treatment for the past 6 months - Other diseases at increased risk for RSV disease: - Chronic kidney disease - Chronic moderate to severe liver disease - Neurologic or neuromuscular conditions - Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as premenarche, hysterectomy, bilateral oophorectomy, bilateral salpingectomy or post-menopause. - Female participants of childbearing potential may be enrolled in the study, if the participant: - has practiced adequate contraception from 1 month prior to study intervention administration, and - has a negative pregnancy test on the day of study prior to intervention administration, and - has agreed to continue adequate contraception for at least 1 month after completion of the study intervention administration. Specific inclusion criteria for all participants in Cohort 2 • A male or female participant >=60 YOA at the time of the study intervention administration. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease are allowed to participate in this study if considered medically stable by the investigator. • Participants living in the general community or in an assisted-living facility that provides minimal assistance, such that the participant is primarily responsible for self-care and activities of daily living. Exclusion Criteria: Medical conditions - Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., current malignancy, human immunodeficiency virus) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required). - History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention. - Unstable chronic illness. - Any history of dementia or any medical condition that moderately or severely impairs cognition. - Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol (e.g., completion of the diary cards, attend study site visits). Study participants may decide to assign a caregiver to help them complete the study procedures. - Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease). - Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe. - Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy - Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study intervention during the period beginning 30 days before the dose of study intervention (Day -29 to Day 1), or planned use during the study period (up to Visit 3, Month 6). - Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the dose of study intervention administration, with the exception of inactivated, subunit and split influenza vaccines or COVID-19 vaccines which can be administered up to 14 days before or from 14 days after the study intervention administration. - Previous vaccination with any RSV vaccine, including investigational RSV vaccines. - Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or administration of long-acting immune-modifying treatments or planned administration at any time up to the End-of-study (EOS). - Up to 3 months prior to the study intervention administration: - For corticosteroids, this will mean prednisone >=20 mg/day, or equivalent. Inhaled, topical and intra-articular steroids are allowed - Administration of immunoglobulins and/or any blood products or plasma derivatives - Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., Tumor Necrosis Factor (TNF)-inhibitors), monoclonal antibodies, antitumoral medication. Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or invasive medical device). Other exclusions: Other exclusions for all participants - History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures. - Bedridden participants. - Planned move during the study period that will prohibit participating in the study until study end. - Participation of any study personnel or their immediate dependents, family, or household members. Other exclusions for Cohort 1 - Pregnant or lactating female participant. - Female planning to become pregnant or planning to discontinue contraceptive precautions within 1 month after study intervention administration.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
RSVPreF3 OA investigational vaccine
1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1;

Locations

Country Name City State
Australia GSK Investigational Site North Melbourne Victoria
Australia GSK Investigational Site St Albans Victoria
Australia GSK Investigational Site St Leonards New South Wales
Australia GSK Investigational Site Tarragindi Queensland
Canada GSK Investigational Site Guelph Ontario
Canada GSK Investigational Site London Ontario
Canada GSK Investigational Site New Westminster British Columbia
Canada GSK Investigational Site Quebec
Canada GSK Investigational Site Québec
Canada GSK Investigational Site Sherbrooke Quebec
Canada GSK Investigational Site St-Charles-Borromée Quebec
Canada GSK Investigational Site Truro Nova Scotia
Canada GSK Investigational Site Victoria British Columbia
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Berlin
Germany GSK Investigational Site Essen Nordrhein-Westfalen
Germany GSK Investigational Site Mainz Rheinland-Pfalz
Germany GSK Investigational Site Wallerfing Bayern
Germany GSK Investigational Site Weinheim Baden-Wuerttemberg
Germany GSK Investigational Site Witten Nordrhein-Westfalen
Germany GSK Investigational Site Wuerzburg Bayern
Japan GSK Investigational Site Ibaraki
Japan GSK Investigational Site Kanagawa
Japan GSK Investigational Site Tokyo
Japan GSK Investigational Site Tokyo
South Africa GSK Investigational Site Bellville
South Africa GSK Investigational Site Boksburg Gauteng
South Africa GSK Investigational Site Mowbray
South Africa GSK Investigational Site Newton
United States GSK Investigational Site Charlottesville Virginia
United States GSK Investigational Site DeSoto Texas
United States GSK Investigational Site Hialeah Florida
United States GSK Investigational Site Knoxville Tennessee
United States GSK Investigational Site Lexington Kentucky
United States GSK Investigational Site Miami Florida
United States GSK Investigational Site North Hollywood California
United States GSK Investigational Site Oakland California
United States GSK Investigational Site Oklahoma City Oklahoma
United States GSK Investigational Site Orlando Florida
United States GSK Investigational Site Phoenix Arizona
United States GSK Investigational Site Rochester New York
United States GSK Investigational Site Silver Spring Maryland
United States GSK Investigational Site Tempe Arizona
United States GSK Investigational Site Walnut Creek California
United States GSK Investigational Site Wenatchee Washington

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Australia,  Canada,  Germany,  Japan,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary RSV-A neutralizing titers expressed as Geometric Mean Titers (GMTs) ratio (RSV-OA over RSV-A-AIR) RSV-A neutralizing titers are given as group GMTs and are expressed as Estimated Dilution 60 (ED60). At 1 month (Day 31) post-RSVPreF3 OA investigational vaccine dose administration
Primary Seroresponse rate (SRR) in RSV-A neutralizing titers SRR is defined as the proportion of participants having a fold increase in neutralizing titers (1 month post-study intervention administration over pre-study intervention administration) greater than or equal to (=) 4. RSV-A neutralizing titers are expressed as Estimated Dilution 60 (ED60). At 1 month (Day 31) post-RSVPreF3 OA investigational vaccine dose administration compared to baseline (Day 1)
Primary RSV-B neutralizing titers expressed as GMT ratio (RSV-OA over RSV-A-AIR) RSV-B neutralizing titers are given as group GMTs and are expressed as Estimated Dilution 60 (ED60). At 1 month (Day 31) post-RSVPreF3 OA investigational vaccine dose administration
Primary SRR in RSV-B neutralizing titers SRR is defined as the proportion of participants having a fold increase in neutralizing titers (1-month post-study intervention administration over pre-study intervention administration) = 4. RSV-B neutralizing titers are expressed as Estimated Dilution 60 (ED60). At 1 month (Day 31) post-RSVPreF3 OA investigational vaccine dose administration compared to baseline (Day 1)
Secondary Percentage of participants reporting solicited administration site events The assessed solicited administration site events are pain, redness and swelling at administration site. During the 4-day follow up period after vaccination (vaccine administered at Day 1)
Secondary Percentage of participants reporting solicited systemic events The assessed solicited systemic events are fever, headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). Fever is defined as temperature >= 38.0 degrees Celsius (°C) /100.4 degrees Fahrenheit (°F), regardless of the location of . measurement. The route for measuring temperature can be oral or axillary. During the 4-day follow up period after vaccination (vaccine administered at Day 1)
Secondary Percentage of participants reporting unsolicited adverse events (AEs) An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. During the 30-day follow up period after vaccination (vaccine administered at Day 1)
Secondary Percentage of participants reporting any serious adverse events (SAEs), related SAEs and fatal SAEs An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of relation to study vaccination. Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination. From study intervention administration (Day 1) up to study end (Month 6 after study intervention administration)
Secondary Percentage of participants reporting any adverse events of special interest (AESIs), including potential immune-mediated diseases (pIMDs) and atrial fibrillation (AF) pIMDs are a subset of AESIs that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. AEs of AF are considered as AESI. From study intervention administration (Day 1) up to study end (Month 6 after study intervention administration)
Secondary RSV-A neutralizing titers expressed as GMTs RSV-A neutralizing titers are given as GMTs and are expressed as Estimated Dilution 60 (ED60). At pre-study intervention administration (Day 1), at Month 1 and Month 6 post-study intervention administration
Secondary RSV-B neutralizing titers expressed as GMTs RSV-B neutralizing titers are given as GMTs and are expressed as Estimated Dilution 60 (ED60). At pre-study intervention administration (Day 1), at Month 1 and Month 6 post-study intervention administration
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03698084 - RESCEU: Defining the Burden of RSV Disease
Completed NCT04090658 - A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults Phase 1
Completed NCT04231968 - A Study of AK0529 in Chinese Infants Hospitalized With RSV Phase 3
Completed NCT03227029 - Evaluating the Infectivity, Safety, and Immunogenicity of Recombinant Live-Attenuated RSV Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age Phase 1
Completed NCT02984280 - Specific Respiratory Infections as Triggers of Acute Medical Events N/A
Withdrawn NCT02864628 - RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults. Phase 1
Completed NCT02873286 - RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults Phase 2
Terminated NCT02948127 - Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age Phase 1
Completed NCT02247726 - RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women. Phase 2
Completed NCT02040831 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1
Completed NCT02237209 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1
Completed NCT01915394 - Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) N/A
Completed NCT01355016 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers Phase 1
Completed NCT00232635 - A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT Phase 2
Completed NCT01155193 - Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany
Not yet recruiting NCT06083623 - A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants Phase 2/Phase 3
Terminated NCT02890381 - Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age Phase 1
Active, not recruiting NCT03422237 - Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age Phase 1
Completed NCT03674177 - A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women Phase 1
Completed NCT01968083 - Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children Phase 1